Cancer combo trial halted early – what went wrong?
NCT ID NCT04779151
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated early, so we have limited data on its effectiveness or safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib and dostarlimab
What this could lead to
If successful, this combination could offer a new treatment option for certain hard-to-treat cancers with DNA repair problems.
What could go wrong
The trial was terminated early, so results are limited. It was a small, early-phase study, and the combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94800, France